Literature DB >> 31814744

First Reported Nosocomial Outbreak Of NDM-5-Producing Klebsiella pneumoniae In A Neonatal Unit In China.

Ziyan Kong1, Rui Cai1, Chen Cheng1, Chuanling Zhang2, Haiquan Kang3, Ping Ma3, Bing Gu1,3.   

Abstract

PURPOSE: Carbapenem-resistant Klebsiella pneumoniae (CRKP) have emerged worldwide and also being a major threat to children and neonate. In this study, we describe a nosocomial outbreak of NDM-5-producing Klebsiella pneumoniae in neonatal unit of a teaching hospital in China from September 2015 to September 2016. PATIENTS AND METHODS: We collected 12 carbapenem-resistant K. pneumoniae outbreak strains from 12 newborns and characterized these isolates for their antimicrobial susceptibility, clone relationships, and multi-locus sequence types using vitek-2 compact system, pulsed-field gel electrophoresis (PFGE) and multi-locus sequence typing (MLST). Resistant genes were detected by using PCR and sequencing. Plasmid conjugation experiment was carried out to determine the transferability of carbapenem resistance. PCR-based replicon typing (PBRT), S1 nuclease-PFGE, and southern blotting were conducted for plasmid profiling.
RESULTS: All 12 K. pneumoniae isolates were resistant to carbapenems and carried bla NDM-5, bla TEM-1 and bla SHV-11. Furthermore, PFGE analysis showed that NDM-5-producing K. pneumoniae were clonally related and MLST assigned them to sequence type 337. Conjugative assays showed that plasmids harboring bla NDM-5 gene were self-transmissible. Plasmid analysis suggested that all bla NDM-5 gene located on a ~45 kb IncX3 type plasmid.
CONCLUSION: To the best of our knowledge, this is the first report of a clone outbreak of bla NDM-5-carrying K. pneumoniae isolates from neonates. There is an urgent need for effective infection control measures to prevent bla NDM-5 variants from becoming epidemic in the neonates in the future.
© 2019 Kong et al.

Entities:  

Keywords:  IncX3; Klebsiella pneumoniae; ST337; blaNDM-5; carbapenemases; neonate

Year:  2019        PMID: 31814744      PMCID: PMC6863125          DOI: 10.2147/IDR.S218945

Source DB:  PubMed          Journal:  Infect Drug Resist        ISSN: 1178-6973            Impact factor:   4.003


Introduction

The continuous emergence of Carbapenem-resistant Klebsiella pneumoniae (CRKP) has become a serious public-health problem worldwide.1 Among the newly emerging carbapenemases, New Delhi metallo-β-lactamase (NDM) has been considered as a major clinical challenge due to its ability to hydrolyzing all β-lactams antibiotics except monobactams and its rapid spread worldwide.2 Since NDM-1 was first identified in a K. pneumoniae isolate from a Swedish patient who had traveled to New Delhi in 2008,3 21 new blaNDM alleles have been discovered in global.4 The rapid evolution of blaNDM genes represents a huge challenge for clinical infection treatment. In 2011, NDM-5 was first identified in a multidrug-resistant Escherichia coli isolate in the UK.5 The NDM-5 enzyme differs from the prevalent NDM-1 at the amino acid positions, which appears to confer elevated resistance to carbapenems and extended-spectrum cephalosporins. Unlike the prevalent NDM-1 enzyme, the identification of NDM-5 enzymes is not common. Among the Enterobacteriaceae, reports of blaNDM-5-harboring K. pneumoniae isolates are sporadic.6–12 In this study, we investigate an outbreak of blaNDM-5-positive K. pneumoniae strains in neonatal unit of a teaching hospital in China with the aim of determining the molecular basis of the emerging ST337 carbapenem-resistant K. pneumoniae isolates responsible for this outbreak. As far as we know, this is the first description of NDM-5-producing K. pneumoniae nosocomial outbreak in the neonatal ward.

Materials And Methods

Collection Of Clinical Isolates And Patients

The study was conducted in the Department of Neonatology at a teaching hospital in Jiangsu Province, China. There are 120 beds in the Department of Neonatology, with an estimated population of 5000 patient visits per year. From September 2015 to September 2016, 12 non-duplicated strains of carbapenem-resistant K. pneumoniae were isolated from inpatients in newborn medicine ward. Strain identification was performed by Matrix-Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry (MALDI-TOF MS; Bruker Daltonik GmbH, Bremen, Germany). In vitro antimicrobial susceptibility testing of isolates was analyzed with VITEK-2 compact system (bioMérieux, Marcy-l’Étoile, France). The electronic medical records of the newborns including patient demographics, neonatal birth information, antimicrobial treatment, and clinical outcomes were retrospectively reviewed.

Antimicrobial Susceptibility Testing

The minimum inhibitory concentrations (MICs) of meropenem (MEM), imipenem (IPM), aztreonam (ATM), ceftazidime (CAZ), cefepime (FEP), cefotaxime (CTX), amoxicillin-clavulanate (AMC), sulbactam/cefoperazone (SCF), piperacillin-tazobactam (TZP), amikacin (AM), levofloxacin (LE), ciprofloxacin (CPFX), compound Sulfamethoxazole (SMZ-TMP), tigecycline (TG) and polymyxin B (PB) were measured by broth microdilution method. Antimicrobial susceptibility testing was interpreted in accordance with the Clinical and Laboratory Standards Institute (CLSI),13 except for sulbactam/cefoperazone, tigecycline and colistin, which were interpreted based on the European Committee for Antimicrobial Susceptibility Testing (EUCAST) criteria.14

Polymerase Chain Reaction (PCR) Amplifications And Sequencing

PCR using the primers mentioned in Table 1 allowed the detection of carbapenemase genes (blaKPC, blaNDM, blaVIM, blaOXA-48 and blaIMP),15–19 common extended-spectrum β-lactamase (ESBL) genes (blaCTX-M-1group, blaCTX-M-2group, blaCTX-M-8 group, blaCTX-M-9 group, blaSHV and blaTEM) and AmpC genes (blaCIT, blaMOX, blaDHA, blaEBC, and blaFOX).20,21 DNA templates were prepared by alkaline lysis method using the kit (MoBio, USA). Amplifications were carried out in 50 µL final volume with 2 µL DNA, 25 µL 2X Taq Master Mix (TaKaRa, Dalian, China), and 2 µM of each primer (Shanghai Sangon, Shanghai, China). PCR conditions for all genes consisted of one cycle at 95°C for 5 mins, followed by 30 cycles at 94°C for 1 min, 72°C for 1 min, and one cycle at 72°C for 5 mins; the annealing step varied depending on the target gene as follows: 55°C/1 min for blaIMP; 59°C/1 min for blaKPC, blaVIM, blaCTX-M-2group, blaMOX; 58°C/1 min for blaNDM, blaCTX-M-8group, blaTEM; 62°C/1 min for blaOXA−48, blaCTX-M-1group, blaDHA, blaFOX; 64°C/1 min for blaCTX-M-9group and blaEBC; 66°C/1 min for blaCIT; 68°C/1 min for blaSHV. Amplified genes were screened by electrophoresis on a 1.5% agarose gel. The positive amplicons were subjected to direct sequencing, and the sequences obtained were compared to reported sequences from GenBank () using BLAST searches.
Table 1

Primers Used For Amplification Of The Resistance Genes Of K. pneumoniae In This Study

Resistance GenePrimerSize Of PCR Product (bp)References
blaKPCF: ATG TCA CTG TAT CGC CGT C88215
R: TTA CTG CCC GTT GAC GCC
blaNDMF: GAAGCTGAGCACCGCATTAG98216
R: GGGCCGTATGAGTGATTGC
blaVIMF: GCMCTTCTCGCGGAGATTGA25717
R: TGCGCAGCACCRGGATAGA
blaOXA-48F: TTGGTGGCATCGATTATCGG74318
R: GAGCACTTCTTTTGTGATGGC
blaIMPF: CTACCGCAGCAGAGTCTTTG58719
R: AACCAGTTTTGCCTTACCAT
blaCTX-M1groupF: CAGCGCTTTTGCCGTCTAAGC94520
F: GGCCCATGGTTAAAAAATCACTGC
blaCTX-M2 groupF: CTC AGA GCA TTC GCC GCT CA84820
R: CCG CCG CAG CCA GAA TAT CC
blaCTX-M8groupF: ACTTCAGCCACACGGATTCA102420
R: CGA GTA CGT CAC GAC GAC TT
blaCTX-M9groupF: GTTACAGCCCTTCGGCGATGATTC88120
R: GCGCATGGTGACAAAGAGAGTGCAA
blaSHVF: CGCCGGGTTATTCTTATTTGTCGC101720
R: TCT TTCCGATGCCGCCGCCAGTCA
blaTEMF: ATA AAATTCTTGAAGACGAAA108020
R: GACAGTTACCAATGCTTAATCA
blaCITF: TGGCCAGAACTGACAGGCAA46221
R: TTTCTCCTGAACGTGGCTGG
blaMOXF: GCTGCTCAAGGAGCACAGGAT52021
R: CACATTGACATAGGTGTGGTGC
blaDHAF: AACTTTCACAGGTGTGCTGGGT40521
R: CCGTACGCATACTGGCTTTGC
blaEBCF: TCGGTAAAGCCGATGTTGCGG30221
R: CTTCCACTGCGGCTGCCAGTT
blaFOXF: AACATGGGGTATCAGGGAGATG19021
R: CAAAGCGCGTAACCGGATTGG
Primers Used For Amplification Of The Resistance Genes Of K. pneumoniae In This Study

Molecular Typing

The clonal relationships of the NDM-5 producing K. pneumoniae isolates were analyzed using Pulsed-field gel electrophoresis (PFGE) and whole genomic DNA was digested with XbaI restriction endonuclease (TaKaRa, Dalian, China). Salmonella enterica serotype Braenderup H9812 was used as a marker. The PFGE patterns were compared using BioNumerics software version 5.10, with a cutoff at 90% similarity to indicate identical PFGE types (pulsotypes). Multi-locus sequence typing was also performed for genotyping. Seven housekeeping genes (infB, pgi, mdh, phoE, gapA, tonB and rpoB) were amplified by using primer sequences described on the MLST website.22 Sequence types (STs) were assigned using the MLST database ().

Conjugation Assay

A conjugation assay was performed between the isolates harboring blaNDM-5 as donors and E. coli 600 (rifampicin-resistant strain) as a recipient.23 Transconjugants were selected on Brain Heart Infusion agar containing 600 µg/mL rifampicin and 2 µg/mL imipenem for 24 hrs at 35°C and the presence of the blaNDM-5 gene was confirmed by PCR sequencing. Susceptibility testing of the transconjugants was performed as well.

Plasmid Analysis

Plasmid incompatibility types of the transconjugants were identified by PCR-based replicon typing as reported previously.24,25 S1-PFGE and Southern blotting were performed to isolate and localize the resistant plasmid carrying blaNDM-5 gene. Briefly, blaNDM-5 positive isolates embedded in gold agarose gel plugs were digested with S1 nuclease (TaKaRa Biotechnology, Dalian, China) and plasmid DNA was electrophoresed on a CHEF-mapper XA (PFGE) system (Bio-Rad, USA). Subsequently, the DNA fragments were blotted onto a positive-charged nylon membrane (Millipore, USA) and hybridized with blaNDM-5 specific probe according to the protocol of DIG High Prime DNA Labeling and Detection Starter Kit I (Roche Applied Sciences, Penzberg, Germany).

Results

Clinical Characteristics Of 12 K. pneumoniae

In September 2015, a premature baby was born in this hospital with neonatal pneumonia and neonatal respiratory distress syndrome (case 1). The first carbapenem-resistant K. pneumoniae strain was isolated from the sputum culture on September 10, 2015. The first baby’s mother suffered from acute gastroenteritis in the 7th month of pregnancy and hospitalized in another hospital in Jiangsu. After 1 day, another neonate also had neonatal respiratory distress syndrome and was positive for carbapenem-resistant K. pneumoniae in sputum culture. No other isolates were detected between October and November. However, since December 2015, the isolation rate of the strain has increased significantly, and 10 strains have been isolated from December 2015 to September 2016. By September 2016, 12 cases had occurred in newborn medicine ward in total. All the 12 neonates were improved after receiving various antimicrobial therapies including moxalactam, ceftazidime, cefotaxime, amoxicillin-sulbactam, amoxicillin-clavulanate and piperacillin-tazobactam. The 12 NDM-5-positive K. pneumoniae strains were detected from urine (n=1), blood (n=2) and sputum (n=9), respectively. Eleven newborns had neonatal pneumonia, three had neonatal respiratory distress syndrome, and two neonatal sepsis. Four newborns were premature, one of whom were very low birth weight infant. The demographic and clinical profiles of the 12 newborns involved in the outbreak of NDM-5-positive K. pneumoniae isolates are shown in Table 2.
Table 2

Clinical Features Of The Neonates In This Study

CaseSexPregnancy Duration (wk)Birth wt (g)Dates Of Hospital StayDate Isolate IdentifiedSpecimenType(s) Of InfectionsAntimicrobial TherapyClinical Outcome
1M3530001 Sep–17 Sep 201510 Sep 2015SputumNP, NRDSMOXImprovement
2M3616002 Sep–28 Sep 201511 Sep 2015SputumNRDSMOX+CAZImprovement
3M40340018 Dec 2015–13 Jan 201623 Dec 2015SputumNPCAZImprovement
4F42310022 Dec 2015–6 Jan 201624 Dec 2015SputumNPCTXImprovement
5M39350030 Dec 2015–8 Jan 201631 Dec 2015SputumNPMOX+AMSImprovement
6F40330029 Dec 2015–7 Jan 20161 Jan 2016UrineNPMOX+AMSImprovement
7F40330018 Jan −7 Feb 201626 Jan 2016SputumNPMOX+AMSImprovement
8M3934507 Feb −14 Mar 20168 Mar 2016BloodNP, NSMOX +AMCImprovement
9F38330020 Jul–2 Aug 201629 Jul 2016SputumNP, NRDSCAZImprovement
10M34150022 Aug–2 Oct 201627 Aug 2016SputumNP, NRDSCAZ+TZPImprovement
11M3525903 Sep–14 Sep 20164 Sep 2016SputumNPCAZImprovement
12F40300010 Sep–20 Sep 201618 Sep 2016BloodNP, NSMOX +AMCImprovement

Abbreviations: M, male; F, female; NP, neonatal pneumonia; NRDS, neonatal respiratory distress syndrome; NS, neonatal sepsis; MOX, moxalactam; CAZ, ceftazidime; CTX, cefotaxime; AMS, amoxicillin-sulbactam; AMC, amoxicillin-clavulanate; TZP, piperacillin-tazobactam.

Clinical Features Of The Neonates In This Study Abbreviations: M, male; F, female; NP, neonatal pneumonia; NRDS, neonatal respiratory distress syndrome; NS, neonatal sepsis; MOX, moxalactam; CAZ, ceftazidime; CTX, cefotaxime; AMS, amoxicillin-sulbactam; AMC, amoxicillin-clavulanate; TZP, piperacillin-tazobactam.

Antibiotic Susceptibility Testing And Detection Of Resistance Determinants

All 12 clinical isolates exhibited resistance to meropenem, imipenem, aztreonam, cefotaxime, ceftazidime, cefepime, sulbactam-cefoperazone, amoxicillin-clavulanate and piperacillin-tazobactam but remained susceptible to levofloxacin, ciprofloxacin, amikacin, compound sulfamethoxazole, tigecycline and polymixin B. All 12 isolates carried the blaNDM-5, blaSHV-11, and blaTEM-1 genes. The other resistance genes present in clinical K. pneumoniae isolates were not detected. The antibiotic resistance characteristics of the 12 NDM-5-positive K. pneumoniae isolates and their corresponding transconjugants are shown in Table 3.
Table 3

Antibiotic Resistance Characteristics Of The 12 NDM-5-Positive K. pneumoniae Isolates And Their Corresponding Transconjugants

Isolate No.Antimicrobial Resistance GenesMinimum Inhibitory Concentration (μg/mL)
MEMIPMATMCTXCAZFEPAMCPFXLEAMCTZPSCFSMZ-TMPTGPB
KP1blaNDM-5, SHV-11, TEM-18≥16≥64≥64≥64≥32≤20.51≥32≥128≥64≤202≤0.5
KP2blaNDM-5, SHV-11, TEM-1≥16≥1616≥64≥64≥32≤2≤0.25≤0.12≥32≥128≥64≤20≤0.5≤0.5
KP3blaNDM-5, SHV-11, TEM-1≥16≥16≥64≥64≥64≥32≤211≥32≥128≥64≤202≤0.5
KP4blaNDM-5, SHV-11, TEM-1≥16≥16≥64≥64≥64≥32≤20.51≥32≥128≥64≤202≤0.5
KP5blaNDM-5, SHV-11, TEM-1≥16≥16≥64≥64≥64≥32≤2≤0.25≤0.12≥32≥128≥64≤202≤0.5
KP6blaNDM-5, SHV-11, TEM-1≥16≥16≥64≥64≥64≥32≤20.51≥32≥128≥64≤202≤0.5
KP7blaNDM-5, SHV-11, TEM-1≥16≥16≥64≥64≥64≥32≤20.51≥32≥128≥64≤202≤0.5
KP8blaNDM-5, SHV-11, TEM-1≥16≥16≥64≥64≥64≥32≤211≥32≥128≥64≤202≤0.5
KP9blaNDM-5, SHV-11, TEM-1≥16≥16≥64≥64≥64≥32≤20.51≥32≥128≥64≤202≤0.5
KP10blaNDM-5, SHV-11, TEM-18≥16≥64≥64≥64≥32≤2≤0.25≤0.25≥32≥128≥64≤202≤0.5
KP11blaNDM-5, SHV-11, TEM-1≥16≥16≥64≥64≥64≥32≤20.51≥32≥128≥64≤202≤0.5
KP12blaNDM-5, SHV-11, TEM-1≥16≥16≥64≥64≥64≥32≤20.51≥32≥128≥64≤202≤0.5
EC600-1blaNDM-58≥16≤1≥64≥644≤2≤0.25≤0.12≥32≥128≥64≤20≤0.5≤0.5
EC600-2blaNDM-588≤1≥64≥644≤20.5≤0.12≥32≥128≥64≤20≤0.5≤0.5
EC600-3blaNDM-58≥16≤1≥64≥644≤2≤0.25≤0.12≥32≥128≥64≤20≤0.5≤0.5
EC600-4blaNDM-5≥16≥16≤1≥64≥648≤20.5≤0.12≥32≥128≥64≤20≤0.5≤0.5
EC600-5blaNDM-58≥16≤1≥64≥648≤20.5≤0.12≥32≥128≥64≤20≤0.5≤0.5
EC600-6blaNDM-5≥16≥16≤1≥64≥648≤20.5≤0.12≥32≥128≥64≤20≤0.5≤0.5
EC600-7blaNDM-54≥16≤1≥64≥648≤20.5≤0.12≥32≥128≥64≤20≤0.5≤0.5
EC600-8blaNDM-5≥16≥16≤1≥64≥644≤2≤0.25≤0.12≥32≥128≥64≤20≤0.5≤0.5
EC600-9blaNDM-54≥16≤1≥64≥644≤20.5≤0.12≥32≥128≥64≤20≤0.5≤0.5
EC600-10blaNDM-58≥16≤1≥64≥644≤2≤0.25≤0.12≥32≥128≥64≤20≤0.5≤0.5
EC600-11blaNDM-54≥16≤1≥64≥648≤20.5≤0.12≥32≥128≥64≤20≤0.5≤0.5
EC600-12blaNDM-58≥16≤1≥64≥644≤2≤0.25≤0.12≥32≥128≥64≤20≤0.5≤0.5
EC600≤1≤1≤1≤1≤1≤1≤2≤0.25≤0.12222≤20≤0.5≤0.5

Abbreviations: MEM, meropenem; IPM, imipenem; ATM, aztreonam; CAZ, ceftazidime; CTX, cefotaxime; FEP, cefepime; AM, amikacin; CPFX, ciprofloxacin; LE, levofloxacin; AMC, amoxicillin-clavulanate; TZP, piperacillin/tazobactam; SCF, sulbactam/cefoperazone; SMZ-TMP, compound Sulfamethoxazole; TG, tigecycline; PB, polymixin B.

Antibiotic Resistance Characteristics Of The 12 NDM-5-Positive K. pneumoniae Isolates And Their Corresponding Transconjugants Abbreviations: MEM, meropenem; IPM, imipenem; ATM, aztreonam; CAZ, ceftazidime; CTX, cefotaxime; FEP, cefepime; AM, amikacin; CPFX, ciprofloxacin; LE, levofloxacin; AMC, amoxicillin-clavulanate; TZP, piperacillin/tazobactam; SCF, sulbactam/cefoperazone; SMZ-TMP, compound Sulfamethoxazole; TG, tigecycline; PB, polymixin B. PFGE typing revealed that all 12 K. pneumoniae isolates in this outbreak shared highly similar PFGE patterns, which suggests that the 12 isolates were clonally related (Figure 1). MLST analysis showed that these 12 strains, KP1–12, belonged to ST337 with the allelic profile 2-1-11-1-1-1-13.
Figure 1

Dendrogram of PFGE profiles of 12 blaNDM-5-positive Klebsiella pneumoniae isolates.

Dendrogram of PFGE profiles of 12 blaNDM-5-positive Klebsiella pneumoniae isolates.

Conjugation And Plasmid Analysis

In our study, all of plasmids carried blaNDM-5 gene from the donor carbapenem-resistant K pneumoniae strains were successfully transferred to the recipient Escherichia coli EC600. The corresponding transconjugants are termed EC600-1–EC600-12, respectively. The MIC values of 12 the transconjugants were tested, and all transconjugants exhibited resistance to carbapenem and enzyme inhibitors (Table 3). As shown in Figure 2, S1-PFGE and Southern blot hybridization using a DIG-labeled blaNDM−5 with incompatibility group-specific probe revealed that blaNDM-5 was located on the nearly same size (~45 kb) IncX3 plasmids.
Figure 2

blaNDM-5-carrying plasmid analysis (Top: S1-nuclease PFGE patterns; Bottom: Southern hybridization of the blaNDM-5 probe, which was hybridized to the roughly 45 kb plasmid to confirm the presence of the resistant plasmid in the 12 ST337 carbapenem-resistant K. pneumoniae strains). Lane M: marker (Salmonella H9812); KP1 to KP12: Klebsiella pneumoniae outbreak strains.

blaNDM-5-carrying plasmid analysis (Top: S1-nuclease PFGE patterns; Bottom: Southern hybridization of the blaNDM-5 probe, which was hybridized to the roughly 45 kb plasmid to confirm the presence of the resistant plasmid in the 12 ST337 carbapenem-resistant K. pneumoniae strains). Lane M: marker (Salmonella H9812); KP1 to KP12: Klebsiella pneumoniae outbreak strains.

Discussion

Carbapenem-resistant Enterobacteriaceae are an emerging problem, which spreads among our most vulnerable populations, children.26 Many carbapenem resistance genes, such as blaKPC-2,21 blaNDM-1,27 blaOXA-48,28 blaOXA-232 and blaIMP-38,29,30 have been found in K. pneumoniae outbreak strains in the newborn. Although NDM-1 enzyme was previously reported as the most prevalent type of carbapenemase in children,31 our current results suggested that the emergence of NDM-5-producing K. pneumoniae caused nosocomial outbreak in neonatal unit. Our research team previously found high prevalence of blaNDM-5 variants among carbapenem-resistant E. coli in Northern Jiangsu Province.32 Based on analysis of previous articles, this is the first identification of blaNDM-5-harboring K pneumoniae outbreak strains in the neonatal infection. In this study, we aimed to identify the microbial resistance characteristics and transmission mechanism of CPKP infections caused by NDM-5-producing K. pneumoniae isolates, which may help to prevent the blaNDM-5 from becoming epidemic in neonates. Previous study found that premature birth and very low birth weight are associated with neonatal nosocomial infections with carbapenem-resistant Enterobacteriaceae.33 In this study, 33.3% and 8.3% of the 12 newborns had premature birth and very low birth weight, respectively. During the study period, 7.0% and 3.15% of all patients in the neonatal unit had premature birth and very low birth weight, respectively. Newborns at high risk should be of the greatest concern in the future when performing procedures to prevent CRKP infection. Compared to adults, children have more limited therapeutic options.34 In our study, all the clinical strains were susceptible to tigecycline and colistin in vitro. However, tigecycline is not recommended for children due to the risk of dental staining and colistin is not currently used in clinical treatment of children in China. Besides, aminoglycosides and fluoroquinolones are also rarely used for children due to their nephrotoxicity and ototoxicity.35 Clinical data show that all the 12 neonates were improved after receiving various antimicrobial therapies including moxalactam, ceftazidime, cefotaxime, amoxicillin, sulbactam, amoxicillin-clavulanate and piperacillin-tazobactam. In this study, 12 newborns responded to treatment with these agents, which seems inconsistent with the antibiotic resistance characteristics of the clinical isolates. We assumed when these agents are combined, synergistic bactericidal action against pathogens may be achieved in vivo.36 The isolates detected from sputum samples were presumed to be the flora colonized in the respiratory tract rather than the real infectious pathogen. PFGE analysis showed that 12 clinical strains shared highly similar PFGE patterns in this outbreak. This implied that the outbreak of NDM-5-producing K. pneumoniae was because of clone spread and the first newborn might be the source of this outbreak. The first baby’s mother was hospitalized for acute gastroenteritis during pregnancy and had high-risk factors for intrauterine infection. Although the NDM-5-producing K. pneumoniae strain was not detected from the mother, we assumed that a small number of these strains might potentially have been colonized in the mother’s body and infected the fetus through the fetal circulation. Then, the CRKP isolate spread among patients in the neonatal ward, more research would be needed to uncover it in the future. It is noteworthy that blaNDM-5 were not only reported in clinical specimens but also in hospital environmental such as the incubator water and the sharing of breast milk.37,38 Hence, we cannot deny that the hospital environment may be the diffusion reservoirs of NDM-5-producing bacteria. Regrettably, the origin of the NDM-5-producing strains in our study is still unknown. Personal contact between the caregivers and the newborns hospitalized in the same ward is the most likely route of the transmission of the isolates. Hospital infection department took strict measures to control the outbreak in the hospital. First, pre-screening of carbapenem-resistant Enterobacteriaceae(CRE) in sputum samples and rectal swabs were introduced before admission to the neonatal medical ward. Second, strict isolation procedures were implemented for patients with CRE infection. Third, it was necessary for medical staff who contact with patients infected with CRE to go through a disinfection procedure. Finally, the neonatal medical wards where newborns with CRE infection stayed were thoroughly sterilized after the discharge of the patients. The sterilized ward left unoccupied for more than 2 weeks before new patients were admitted. Since the implementation of these strict measures in this neonatal medical ward, no infections due to ST337 NDM-5-producing K. pneumoniae isolates have occurred as of May 2017. Several countries, such as India (ST648),39 Denmark (ST1284),40 Poland (ST418),41 Spain (ST418),42 Japan (ST540),43 and Singapore (ST231),10 have reported infections caused by NDM-5-positive strains since the initial identification of this carbapenemase type in UK (ST648).5 In China, ST167 carbapenemase-producing Escherichia coli is main reservoir of blaNDM-5.44 This is the first identification of NDM-5-producing K. pneumoniae isolate belonged to ST337, which related to CC37, and have only been identified in KPC-2-producing K. pneumoniae in carbapenem-resistant Enterobacteriaceae family. The conjugation experiment showed that the carbapenem resistance phenotype of the 12 clinical isolates could be successfully transferred to the recipient strain EC600. All 12 transconjugants only carried the blaNDM-5, and the blaSHV-11 and blaTEM-1 were not detected. The plasmid analysis showed that all blaNDM-5 were located on the IncX3 plasmids of the same size (with approximate size 45 kb). Notably, IncX3-type plasmids of 45 kb carrying blaNDM-5 genes have been identified in India,6 Australia and Denmark.38,39 Furthermore, previous studies revealed that the IncX3-type plasmids played a significant role in the dissemination of the blaNDM-5 gene among Enterobacteriaceae in China.45 Therefore, there is an urgent need to adopt effective measures to control the spread of this resistant plasmid type. Although international travel previously reported contributed to the global spread of NDM enzyme,3 all patients in our study who carry blaNDM-5 gene have never been abroad. It was assumed that these NDM-5-producing isolates were autochthonous clones that had obtained the plasmid carrying blaNDM-5.44 Notably, recent studies in China have revealed that NDM-5-producing Enterobacteriaceae was identified from pigs, dairy cows, and vegetables.46–48 And, animals and plants were already important sources of drug-resistant strains. There is an urgent need for more epidemiological studies in the future to better understand mechanisms of emergence and dissemination of blaNDM-5 gene in China.

Conclusion

Our study first described the outbreak of ST337 NDM-5-producing K. pneumoniae isolates from neonates in China. Moreover, these outbreak strains were also detected to carry blaSHV-11 and blaTEM-1. Their resistance profile may help pediatricians promote the prudent use of antibiotics in child health care. Worldwide surveillance of these ST337 NDM-5 producing K. pneumoniae isolates from neonates and implementation of stricter control measures are urgently needed to prevent these multiple-resistant strains from further disseminating in neonatal ward.
  46 in total

1.  Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR.

Authors:  F Javier Pérez-Pérez; Nancy D Hanson
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

2.  First report of metallo-β-lactamase NDM-5-producing Escherichia coli in Japan.

Authors:  Ryuichi Nakano; Akiyo Nakano; Kenji Hikosaka; Sayoko Kawakami; Naohisa Matsunaga; Miwa Asahara; Shinobu Ishigaki; Taiji Furukawa; Masato Suzuki; Keigo Shibayama; Yasuo Ono
Journal:  Antimicrob Agents Chemother       Date:  2014-09-22       Impact factor: 5.191

3.  Identification of plasmids by PCR-based replicon typing.

Authors:  Alessandra Carattoli; Alessia Bertini; Laura Villa; Vincenzo Falbo; Katie L Hopkins; E John Threlfall
Journal:  J Microbiol Methods       Date:  2005-06-02       Impact factor: 2.363

4.  Risk factors and clinical outcomes for carbapenem-resistant Gram-negative late-onset sepsis in a neonatal intensive care unit.

Authors:  I Nour; H E Eldegla; N Nasef; B Shouman; H Abdel-Hady; A E Shabaan
Journal:  J Hosp Infect       Date:  2017-06-03       Impact factor: 3.926

5.  Various Sequence Types of Escherichia coli Isolates Coharboring blaNDM-5 and mcr-1 Genes from a Commercial Swine Farm in China.

Authors:  Ling-Han Kong; Chang-Wei Lei; Su-Zhen Ma; Wei Jiang; Bi-Hui Liu; Yong-Xiang Wang; Ru Guan; Shuai Men; Qi-Wu Yuan; Guang-Yang Cheng; Wen-Cheng Zhou; Hong-Ning Wang
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

6.  Resistance of strains producing extended-spectrum beta-lactamases and genotype distribution in China.

Authors:  Yunsong Yu; Shujuan Ji; Yagang Chen; Weilin Zhou; Zeqing Wei; Lanjuan Li; Yilin Ma
Journal:  J Infect       Date:  2006-03-13       Impact factor: 6.072

7.  Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study.

Authors:  Karthikeyan K Kumarasamy; Mark A Toleman; Timothy R Walsh; Jay Bagaria; Fafhana Butt; Ravikumar Balakrishnan; Uma Chaudhary; Michel Doumith; Christian G Giske; Seema Irfan; Padma Krishnan; Anil V Kumar; Sunil Maharjan; Shazad Mushtaq; Tabassum Noorie; David L Paterson; Andrew Pearson; Claire Perry; Rachel Pike; Bhargavi Rao; Ujjwayini Ray; Jayanta B Sarma; Madhu Sharma; Elizabeth Sheridan; Mandayam A Thirunarayan; Jane Turton; Supriya Upadhyay; Marina Warner; William Welfare; David M Livermore; Neil Woodford
Journal:  Lancet Infect Dis       Date:  2010-08-10       Impact factor: 25.071

8.  Outbreak of extended-spectrum β-lactamase-producing Escherichia coli transmitted through breast milk sharing in a neonatal intensive care unit.

Authors:  K Nakamura; M Kaneko; Y Abe; N Yamamoto; H Mori; A Yoshida; K Ohashi; S Miura; T T Yang; N Momoi; K Kanemitsu
Journal:  J Hosp Infect       Date:  2015-05-15       Impact factor: 3.926

9.  blaNDM-5-Bearing IncFII-Type Plasmids of Klebsiella pneumoniae Sequence Type 147 Transmitted by Cross-Border Transfer of a Patient.

Authors:  Juyoun Shin; Jin Yang Baek; Sun Young Cho; Hee Jae Huh; Nam Yong Lee; Jae-Hoon Song; Doo Ryeon Chung; Kwan Soo Ko
Journal:  Antimicrob Agents Chemother       Date:  2016-01-11       Impact factor: 5.191

10.  High Prevalence of bla NDM Variants Among Carbapenem-Resistant Escherichia coli in Northern Jiangsu Province, China.

Authors:  Ruru Bi; Ziyan Kong; Huimin Qian; Fei Jiang; Haiquan Kang; Bing Gu; Ping Ma
Journal:  Front Microbiol       Date:  2018-11-13       Impact factor: 5.640

View more
  7 in total

1.  NDM-1 Carbapenemase-Producing Enterobacteriaceae are Highly Susceptible to Ceragenins CSA-13, CSA-44, and CSA-131.

Authors:  Sylwia Joanna Chmielewska; Karol Skłodowski; Ewelina Piktel; Łukasz Suprewicz; Krzysztof Fiedoruk; Tamara Daniluk; Przemysław Wolak; Paul B Savage; Robert Bucki
Journal:  Infect Drug Resist       Date:  2020-09-28       Impact factor: 4.003

2.  Emergence of NDM-5-Producing Carbapenem-Resistant Klebsiella pneumoniae and SIM-Producing Hypervirulent Klebsiella pneumoniae Isolated from Aseptic Body Fluid in a Large Tertiary Hospital, 2017-2018: Genetic Traits of blaNDM-Like and blaSIM-Like Genes as Determined by NGS.

Authors:  Qi Li; Jiaying Zhu; Jianbang Kang; Yan Song; Donghong Yin; Qian Guo; Junli Song; Yan Zhang; Shuyun Wang; Jinju Duan
Journal:  Infect Drug Resist       Date:  2020-09-04       Impact factor: 4.003

3.  Co-Production of NDM-1, CTX-M-9 Family and mcr-1 in a Klebsiella pneumoniae ST4564 Strain in China.

Authors:  Xinchun Wang; Qi Li; Jianbang Kang; Zheng Zhang; Yan Song; Donghong Yin; Qian Guo; Junli Song; Xiaoxia Li; Shuyun Wang; Jinju Duan
Journal:  Infect Drug Resist       Date:  2021-02-05       Impact factor: 4.003

4.  Clinical Molecular Epidemiology of Carbapenem-Resistant Klebsiella pneumoniae Among Pediatric Patients in Jiangsu Province, China.

Authors:  Ziyan Kong; Xuemei Liu; Chenxi Li; Siyun Cheng; Fei Xu; Bing Gu
Journal:  Infect Drug Resist       Date:  2020-12-22       Impact factor: 4.003

5.  Emergence of NDM-5 Producing Carbapenem-Resistant Klebsiella aerogenes in a Pediatric Hospital in Shanghai, China.

Authors:  Fen Pan; Qi Xu; Hong Zhang
Journal:  Front Public Health       Date:  2021-02-25

6.  Resistance Phenotype and Molecular Epidemiology of Carbapenem-Resistant Klebsiella pneumoniae Isolated from Nanjing Children's Hospital in Jiangsu Province, China.

Authors:  Guixiang Tao; Hua Tan; Jingjing Ma; Qian Chen
Journal:  Infect Drug Resist       Date:  2022-09-14       Impact factor: 4.177

7.  Molecular Epidemiology and Drug Resistant Mechanism of Carbapenem-Resistant Klebsiella pneumoniae in Elderly Patients With Lower Respiratory Tract Infection.

Authors:  Chunhong Shao; Wei Wang; Shuang Liu; Zhijun Zhang; Meijie Jiang; Fusen Zhang
Journal:  Front Public Health       Date:  2021-05-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.